Abstract:Envelope proteins drive virus and host-cell membrane fusion to achieve virus entry. Fusogenic proteins are classified into structural classes that function with remarkable mechanistic similarities. Fusion proceeds through coordinated movements of protein domains in a sequence of orchestrated steps. Structures for the initial and final conformations are available for several fusogens, but folding intermediates have largely remained unresolved and interdependency between regions that drive conformational rearrangements is not well understood. Chikungunya virus (CHIKV) particles display heterodimers of envelope proteins E1 and E2 associated as trimeric spikes that respond to acidic pH to trigger fusion. We have followed experimental evolution of CHIKV under the selective pressure of a novel small-molecule entry inhibitor. Mutations arising from selection mapped to two residues located in distal domains of E2 and E1 heterodimer and spikes. Here, we pinpointed the antiviral mode of action to inhibition of fusion. Phenotypic characterization of recombinant viruses indicated that the selected mutations confer a fitness advantage under antiviral pressure, and that the double-mutant virus overcame antiviral inhibition of fusion while single-mutants were sensitive. Further supporting a functional connection between residues, the double-mutant virus displayed a higher pH-threshold for fusion than single-mutant viruses. Finally, mutations implied distinct outcomes of replication and spreading in mice, and infection rates in mosquitoes underscoring the fine-tuning of envelope protein function as a determinant for establishment of infection. Together with molecular dynamics simulations that indicate a link between these two residues in the modulation of the heterodimer conformational rearrangement, our approach captured an otherwise unresolved interaction. Importance. CHIKV is a reemergent pathogen that has caused large outbreaks in the twenty years. There are no available antiviral therapies and a vaccine has only recently been approved. Here, we describe the mode of action of a novel inhibitor designed against CHIKV envelope proteins heterodimer that blocks entry at the stage of fusion between virus and host membranes. Fusion is common to the entry of enveloped viruses. Virus envelope proteins drive fusion undergoing a series of transitions from an initial metastable conformational state to a more stable post-fusion state. Intermediate conformations are transient and have mostly remained inaccessible to structure determination. In this study, directed evolution of resistance to antiviral inhibition of fusion uncovered a functional interaction between two residues residing in domains that are apart in both the pre-fusion and post-fusion states. Thus, our approach allowed gaining insight into the molecular detail of the inner working of virus fusion machinery.

Deep mutationally scanned (DMS) CHIKV E3/E2 virus library maps viral amino acid preferences and predicts viral escape mutants of neutralizing CHIKV antibodies

Identifying novel chemical matter against the Chikungunya virus nsP3 macrodomain through crystallographic fragment screening

A Small Antigenic Determinant of the Chikungunya Virus E2 Protein Is Sufficient to Induce Neutralizing Antibodies which Are Partially Protective in Mice

Expression of anti-chikungunya single-domain antibodies in transgenic Aedes aegypti reduces vector competence for chikungunya virus and Mayaro virus

Gene Mutations and Molecular Evolution of the Chikungunya Virus E1 and E2 from 2014 to 2019

Structural basis of Chikungunya virus inhibition by monoclonal antibodies

Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.

Identification of immunogenic and cross-reactive chikungunya virus-specific CD4+ T cell epitopes in chronic chikungunya viral arthritic disease in humans

Stabilization of a Broadly Neutralizing Anti-Chikungunya Virus Single Domain Antibody

Antagonism of Mosquito Innate Immunity by the Chikungunya Virus Nsp3 Protein

Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines

Interaction of chikungunya virus glycoproteins with macrophage factors controls virion production

Evolution of antiviral resistance captures a transient interdomain functional interaction between chikungunya virus envelope glycoproteins

Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.

Antigenicity and immunogenicity of chikungunya virus-like particles from mosquito cells

Highly Potent Multivalent VHH Antibodies Against Chikungunya Isolated from an Alpaca Naïve Phage Display Library.

A chikungunya fever vaccine utilizing an insect-specific virus platform

Development of a Novel Multi-Epitope Vaccine Based on Capsid and Envelope Protein Against Chikungunya Virus

Discovery of a cell-active chikungunya virus nsP2 protease inhibitor using a covalent fragment-based screening approach

An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses